Terms: = Skin cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
383 results:
1. Divergent local and systemic antitumor response in primary uveal melanomas.
Lucibello F; Lalanne AI; Le Gac AL; Soumare A; Aflaki S; Cyrta J; Dubreuil L; Mestdagh M; Salou M; Houy A; Ekwegbara C; Jamet C; Gardrat S; Le Ven A; Bernardeau K; Cassoux N; Matet A; Malaise D; Pierron G; Piperno-Neumann S; Stern MH; Rodrigues M; Lantz O
J Exp Med; 2024 Jun; 221(6):. PubMed ID: 38563818
[TBL] [Abstract] [Full Text] [Related]
2. Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-pd1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Fabre M; Lamoureux A; Meunier L; Samaran Q; Lesage C; Girard C; Du Thanh A; Moulis L; Dereure O
Melanoma Res; 2024 Jun; 34(3):241-247. PubMed ID: 38546723
[TBL] [Abstract] [Full Text] [Related]
3. Treatments on the horizon for locally advanced basal cell carcinoma.
Idriss MH; Stull CM; Migden MR
Cancer Lett; 2024 May; 589():216821. PubMed ID: 38521198
[TBL] [Abstract] [Full Text] [Related]
4. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.
Su DG; Schoenfeld DA; Ibrahim W; Cabrejo R; Djureinovic D; Baumann R; Rimm DL; Khan SA; Halaban R; Kluger HM; Olino K; Galan A; Clune J
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519058
[TBL] [Abstract] [Full Text] [Related]
5. Tumor-infiltrating macrophage associated lncRNA signature in cutaneous melanoma: implications for diagnosis, prognosis, and immunotherapy.
Wan Q; Deng Y; Wei R; Ma K; Tang J; Deng YP
Aging (Albany NY); 2024 Mar; 16(5):4518-4540. PubMed ID: 38475660
[TBL] [Abstract] [Full Text] [Related]
6. Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides.
Marques-Piubelli ML; Navarrete J; Ledesma DA; Hudgens CW; Lazcano RN; Alani A; Huen A; Duvic M; Nagarajan P; Aung PP; Wistuba II; Curry JL; Miranda RN; Torres-Cabala CA
Cells; 2024 Feb; 13(5):. PubMed ID: 38474383
[TBL] [Abstract] [Full Text] [Related]
7. Effects of immunogenic cell death-inducing chemotherapeutics on the immune cell activation and tertiary lymphoid structure formation in melanoma.
Zhao H; Zhao Y; Zhang S; Wang Z; Yu W; Dong N; Yang X; Zhang X; Sun Q; Hao X; Ren X
Front Immunol; 2024; 15():1302751. PubMed ID: 38384466
[TBL] [Abstract] [Full Text] [Related]
8. Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
Zhang W; Wang S
Melanoma Res; 2024 Jun; 34(3):215-224. PubMed ID: 38364052
[TBL] [Abstract] [Full Text] [Related]
9. cancer-associated Fibroblast-specific Expression of the Matricellular Protein CCN1 Coordinates Neovascularization and Stroma Deposition in Melanoma Metastasis.
Hutchenreuther J; Nguyen J; Quesnel K; Vincent KM; Petitjean L; Bourgeois S; Boyd M; Bou-Gharios G; Postovit LM; Leask A
Cancer Res Commun; 2024 Feb; 4(2):556-570. PubMed ID: 38363129
[TBL] [Abstract] [Full Text] [Related]
10. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
[TBL] [Abstract] [Full Text] [Related]
11. A prediction model for response to immune checkpoint inhibition in advanced melanoma.
van Duin IAJ; Verheijden RJ; van Diest PJ; Blokx WAM; El-Sharouni MA; Verhoeff JJC; Leiner T; van den Eertwegh AJM; de Groot JWB; van Not OJ; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; van der Veldt AAM; Vreugdenhil G; Wouters MWJM; Stevense-den Boer MAM; Boers-Sonderen MJ; Kapiteijn E; Suijkerbuijk KPM; Elias SG
Int J Cancer; 2024 May; 154(10):1760-1771. PubMed ID: 38296842
[TBL] [Abstract] [Full Text] [Related]
12. The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma.
Hua S; Wang W; Yao Z; Gu J; Zhang H; Zhu J; Xie Z; Jiang H
J Cancer Res Clin Oncol; 2024 Jan; 150(2):40. PubMed ID: 38279987
[TBL] [Abstract] [Full Text] [Related]
13. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-pd-1 based therapy.
Jacques SK; McKeown J; Grover P; Johnson DB; Zaremba A; Dimitriou F; Weiser R; Farid M; Namikawa K; Sullivan RJ; Rutkowski P; Lebbe C; Hamid O; Zager JS; Michielin O; Neyns B; Nakamura Y; Robert C; Mehnert J; Ascierto PA; Bhave P; Park B; Zimmer L; Mangana J; Mooradian M; Placzke J; Allayous C; Glitza Oliva IC; Mehmi I; Depalo D; Wicky A; Schwarze JK; Roy S; Boatwright C; Vanella V; Long GV; Menzies AM; Lo SN; Carlino MS
Eur J Cancer; 2024 Mar; 199():113563. PubMed ID: 38278007
[TBL] [Abstract] [Full Text] [Related]
14. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
Cannon AC; Budagyan K; Uribe-Alvarez C; Kurimchak AM; Araiza-Olivera D; Cai KQ; Peri S; Zhou Y; Duncan JS; Chernoff J
Oncogene; 2024 Mar; 43(10):729-743. PubMed ID: 38243078
[TBL] [Abstract] [Full Text] [Related]
15. TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy.
Wang S; Xiong Y; Zhang Y; Wang H; Chen M; Li J; Luo P; Luo YH; Hecht M; Frey B; Gaipl U; Li X; Zhao Q; Ma H; Zhou JG
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212124
[TBL] [Abstract] [Full Text] [Related]
16. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
17. pd-1 blockade combined with decitabine to treat refractory peripheral T-cell lymphoma not otherwise specified: A case report and review of literature.
Han X; Liu X; Zhang C; Wen Q; Zhang X
J Cancer Res Ther; 2023 Dec; 19(6):1680-1684. PubMed ID: 38156938
[TBL] [Abstract] [Full Text] [Related]
18. The molecular subtypes and clinical prognosis characteristic of tertiary lymphoid structures-related gene of cutaneous melanoma.
Li J; Chen G; Luo Y; Xu J; He J
Sci Rep; 2023 Dec; 13(1):23097. PubMed ID: 38155221
[TBL] [Abstract] [Full Text] [Related]
19. Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma.
Usta SZ; Uchihashi T; Kodama S; Kurioka K; Inubushi T; Shimooka T; Sugauchi A; Seki S; Tanaka S
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139110
[TBL] [Abstract] [Full Text] [Related]
20. Peripheral B-cell levels predict efficacy and overall survival in advanced melanoma patients under pd-1 immunotherapy.
Liu X; Liu S; Jiang Z; Yang C; Yang X; Li J; Liu H
Immunotherapy; 2024 Mar; 16(4):223-234. PubMed ID: 38126156
[TBL] [Abstract] [Full Text] [Related]
[Next]
